Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × NSCLC × Afatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Observational 1 Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 53 Neoplasms 22 Breast Neoplasms 15 Squamous Cell Carcinoma of Head and Neck 13 Lung Neoplasms 12 Head and Neck Neoplasms 11 Neoplasm Metastasis 8 Carcinoma, Squamous Cell 7 Pancreatic Neoplasms 6 Colorectal Neoplasms 6 Stomach Neoplasms 5 Esophageal Squamous Cell Carcinoma 5 Prostatic Neoplasms 4 Multiple Myeloma 4 Esophageal Neoplasms 4 Lymphoma 3 Hematologic Neoplasms 3 Glioblastoma 3 Brain Neoplasms 3 Adenocarcinoma 3 Urinary Bladder Neoplasms 2 Non-small-cell Lung Cancer With Somatic EGFR Mutations 2 Melanoma 2 Glioma 2 Colonic Neoplasms 2 Adenocarcinoma of Lung 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urologic Neoplasms 1 Urethral Neoplasms 1

Interventions

Pemetrexed 14 Carboplatin 12 osimertinib 10 Drug Therapy 9 aflutinib 8 Gefitinib 7 Radiotherapy 6 Docetaxel 6 Cisplatin 6 anlotinib 5 Radiosurgery 5 pembrolizumab 4 Vinorelbine 4 Paclitaxel 4 Gemcitabine 4 tislelizumab 3 icotinib 3 apatinib 3 HM781-36B 3 Erlotinib Hydrochloride 3 toripalimab 2 spartalizumab 2 rezivertinib 2 camrelizumab 2 Tyrosine Kinase Inhibitors 2 Thalidomide 2 Surgical Procedures, Operative 2 S 1 (combination) 2 Platinum 2 Immune Checkpoint Inhibitors 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01861223 2014-02-25

Afatinib Plus Nimotuzumb for NSCLC

Samsung Medical Center

Phase 1/2 Unknown

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡